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Bacterial lipopolysaccharides ( LPS) are endotoxins. However, t..�ere is 
ample evidence to support its role in immunomodulation. In fact LPS is 
commonly used as a B cell mitogen. The activity of LPS from different 
genera of bacteria varies considerably which makes generalisation of 
characteristics difficult. Despite their lethal consequences, the LPS of 
Mannheimia haemolytica A2 have not been tested for immunomodulatory 
activity. Therefore, the objective of this study is to investigate the 
adjuvant properties of LPS from Mannheimia haemolytica A2 upon 
peripheral and mucosal immunity toward protein antigen. 
The experimentai results indicate that, the group of mice that received 
10 l1g LPS in oil induced anti-BSA IgG response in serum 8....1 .d 
pulmonary antibody response when administered intraperitoneally. 
However, in the IgG and 19A intestinal antibody response, mice received 
10 llg LPS without oil showed significantly high compared to controls 
II 
(p::;;0.05). This indicates that LPS can be used as oral adjuvant to 
enhance response at mucosal level. For the oral immunisation, the 
specific anti-OVA IgG titre in serum and IgA levels in the intestinal fluid 
were significantly high in group that received 500 llg LPS. The oral 
administration of 500 llg LPS also increased the number of anti-OVA 
ASe (antigen secreting cell) observed in spleen, mesentric lymph node 
and Peyer's patch. Hence, LPS from Mannheimia haemolytica A2 does 
stimulate peripheral and mucosal immune responses to an unrelated 
antigen. 
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Lipopolisakarida (LPS) dalam bakteria merupakan sejenis endotoksin. 
Walaubagaimanapun, terdapat bukti yang menyatakan bahawa LPS 
mempunyai peranan sebagai imunomodulator di mana LPS biasanya 
bertindak sebagai mitogen dalam sel B. Aktiviti LPS daripada pel bagai 
genera bakteria sangat meiuas sehingga agak sukar untuk membuat 
pengkelasan. Selain daripada mempunyai sifat-sifat toksin, ujikaji 
terhadap aktiviti imunomodulator masih belum dijalankan terutama 
LPS dari jenis Mannheimia haemolytica A2. Oleh yang demikian, di 
dalam eksperimen ini, beberapa ujikaji tela..lJ. dijalankan untuk menguji 
sarna ada LPS dari jenis Mannheimia haemolytica A2 boleh bertindak 
sebagai 'adjuvant' di dalam sistem periperal dan mukosa terhadap 
antigen. 
Hasil kajian menunjukkan bahawa, kumpulan mencit yang diberi 
suntikan intraperitoneal campuran 10 pg LPS dan II"Jnyak 
menghasilkan antibodi anti-BSA IgG yang tinggi dalam serum dan 
iv 
ekstrak: pUlmonari. Walau bagaimanapun, di dalam ekstrak intestin 
kandungan antibodi IgG dan IgA telah menunjukkan peningkatan yang 
baik daripada kumpulan mencit yang disuntik dengan 10 llg LPS tanpa 
minyak: (p�0.05) berbanding kawalan. Ini mununjukkan bahawa LPS 
boleh diberi secara oral untuk merangsang pembentukkan antibodi di 
dalam sistem mukosa. Keputusan eksperimen menunjukkan bahawa 
500 l1g LPS yang diberi secara oral kepada kumpulan mencit telah 
meningkatkan antibodi anti-OVA IgG dalam serum dan IgA dalam 
ekstrak intestin. Selain daripada meningkatkan paras antibodi, bilangan 
sel-sel limfoid (anti-OVA ASe) juga meningkat terutaIna di dalam organ 
limpa, sel-sel mesentrik dan Peyer's patch. Keputusan ujikaji jelas 
menunjukkan bahawa LPS dari bakteria jenis Mannheimia haemolytica 
A2 boleh merangsang tindakbalas imun di dalam sistem periperal dan 
mukosa terhadap antigen. 
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CHAPTER I 
INTRODUCTION 
Immunomodulators are compounds that can cause either 
suppression or potentiation of the immune system. Immunomodulators 
are used to stimulate immune responses to vaccines. Adjuvants are 
generally considered to be materials that are added to vaccines with the 
intent of potentiating the immune response so that a greater amount of 
antibody is produced. The most common adjuvants that are safe for 
human use are aluminium hydroxide, aluminium phosphate and 
calcium phosphate (Edelman, 1980). Adjuvants that have been used for 
research purposes are oil emulsions which were first used by Le Moignic 
and Pinoy (1916), who found that a suspension of killed Salmonella 
typhimurlum in mineral oil increased the immune response. Freund's 
complete adjuvant (FCA) , a water mineral oil emulsion with killed 
mycobacterium is used extensively to augment the immune response of 
laboratory animals for experimental purposes. Freund's incomplete 
adjuvant (FIA) which is water in oil emulsion without mycobacterium is 
used successfully in veterina..ry vaccines including foot-mouth disease, 
rabies, parainfluenza and Newcastle disease. There are also other 
adjuvants derived from other bacteria and their products. 
They play an important role in the immune response. The common 
bacterial used as adjuvants mainly for experimental purposes include 
mycobacterium, Corynebacterium parvum or Corynebacterium 
granulosum, Bordetella pertussis and lipopolysacharides (Rajesh et al., 
1993). 
Lipopolysacharides (LPS) are common bacterial products that can 
be used as adjuvants. It is a constituent of the outer membrane of gram­
negative bacteria that contains 2,3-dideoxy-D-glucose (DAG), an amino 
sugar attached to a lipid A backbone. LPS has long been known to be a 
potent modulator of immune reactions such as B ceil mitogenicity, 
polyc1onal antibody synthesis, immunogenicity, adjuvanticity, 
macrophage activation, mono kine secretion and regulation of 19A 
responses (Qureshi et aI., 1990). LPS also induces regression of 
spontaneous, L.."lduced and transplanted tumours in laboratory animals. 
Its toxicity which involves pyrogenicity, tumour necrosis and lethality 
has limited exploration of its therapeutic potential in man. However, 
studies have shown that the toxic compound of the LPS molecule can be 
cleaved chemically (Ribi et al., 1986). The dose of LPS and the time of 
exposure will determine the resultant effects that will be seen in the 
host. It has been shown to effect on B ceil but not on T lymphocytes. LPS 
has been suggested to bind non-specifically to the cell surface followed 
by intercalation of its hydrophobic lipid A moiety into the plasma 
membrane (Jacobs, 1992). Others have implicated the involvement of 
specific receptors on the surface (Tahiri & Chaby, 1990). Recently, it has 
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been reported that the existence of membrane-associated LPS and lipid 
A-specific binding proteins on responsive celis, including macrophages, 
lymphocytes and B celis (Hara Kuge et ai., 1990). 
There are many gram-negative bacteria that have been used as a 
source of LPS, particularly members of the enterobacteriaceae 
{Salmonella, Shigella, Escherichia, Proteus, Pseudomonas, Klebsiella, 
Mannheimia (Pasteurella}). Mannheimia haemolytica serotype A2 is the 
most commonly occuring serotype associated with pneumonic 
pasteurellosis in cattle and sheep. Immunological studies have been 
done to determine responses in the respiratory tract using killed M. 
haemolytica A2 (Zamri et al., 1999). Although experimental vaccines 
against pneumonic pasteurellosis have been done including both live 
and killed bacteria (Purdy et ai., 1986), research has attempted to 
identify important immunogenic components of M. haemolytica such as 
iron-regulated outer-membrane proteins (aMPs) (Gilmor et al., 199 1) ,  
carbohydrate-protein subunits (Lesley et al., 1985) and LPS (Confer et 
al., 1986) . The immunomodulatory properties of LPS from M. 
haemolytica A2 have not been studied despite being an important 
pathogen of livestock. Therefore, the objectives of the study are:-
1 .  To extract and purify LPS from Mannheimia haemolytica A2. 
2. To determine the immunostimulatory effect of M. haemolytica A2 LPS 
upon peripheral and mucosal immunity toward model protein 
antigens such as bovine serum albumin (BSA) and ovalbumin (OVA). 
3 
CHAPTER 2 
LITERATURE REVIEW 
2.1 Adjuvants 
The response to an immunogen can be enhanced by the use of 
adjuvants. Adjuvants are compound that potentiate the immune 
response when mixed and administered with antigen. They enhance and 
prolong antibody production and increase effector cell counts (Coleman 
et ai., 1992). From this defi.�ition, it is obvious that adjuvants are useful 
and necessary components of the development of vaccines. An adjuvant 
must be able to increase both amount and duration of antibody and T 
helper cell response. The mode of action of adjuvants was SUID..'Tlarised 
by Chedid et ai., (1975). First, the formation of a depot of antigen at the 
site ofi.."1oculation which is slowly released. Secondly, the presentation of 
antigen to immunocompetent cells and the production of different 
lymphokines such as various interleukins and tumour necrosis factor. 
It has long been known that many adjuvants are surface-active 
agents (Allison, 1979). The importance of surface activity in adjuvanticity 
has been confr med with modern adjuvants. Saponins, lipid A and 
muramyl dipeptide (MDP) derivatives are all surface active 
4 
in that they consist of discrete hydrophilic and hydrophobic domains. 
With the use of adjuvants, less antigen is required, thus reducing 
vaccine production cost (Rajesh et aI., 1993). For many years there has 
been a search to find adjuvants with the ability to potentiate the immune 
response but with minimal side effects. Freund's complete adjuvant 
(FCA) is one of the most potent oil adjuvants described so far and used 
extensively to augment the immune response of laboratory animals for 
experimental purposes. FCA as originally formulated was too toxic to be 
used in human. The water in mineral oil emulsion without Mycobacteria 
is known as Freund's incomplete adjuvant (FIA). FIA was used 
successfully in a number of veterinary vaccines inclu<ii..1'1g foot-and­
mouth disease, rabies, parainfluenza and Newcastle disease. FIA has 
been used in human, particularly with influenza and killed poliomyelitis 
vaccines by enhancing the immunogenicity of the vaccines (Salk, 1977). 
However, FIA is unsuitable for routine human application because of 
previously reponed side effects (Table 2.1). From these classical 
adjuvants, there are many alternative adjuvant that have been used for 
many years such as monophosphoryl lipid A (MPL), Titermax®, saponins, 
liposome, muramyl dipeptide (MDP), lipopolysaccharides (LPS), cholera 
toxin and heat labile enterotoxin. 
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Table 2. 1 : Side effect of FIA (Rajesh et at, 1993) 
Local reaction 
Sterile abscesses and cysts 
Granulomas 
Inflammation 
Carcinogenicity 
Oil induced neoplasm in mice 
Arlacel A induced carcinogenicity in mice 
2. 1 . 1  Monophospho ry l lipid A (MPL) 
MPL is a non-toxic lipid A with the lack of phosphate on the 
reducing end of the disaccharide backbone which has 1000-fold less 
toxic than endotoxin (Ribi, 1984). MPL has immunostimulatory activities 
such as B cell mitogenicity, activation of macrophages,  colony-
stimulating activity and the induction of interleukin-l (IL-l) production 
by human monocytes (Rudbach & Cantrell, 1990). Tomai et aI., ( 1987) 
showed that MPL has an adjuvant activity with poly-L-Iysine antigen in 
LPS-hyporesponsive C3H/HeJ and C57BL/ 10ScN mice and in aging 
BALB/c mice, which have a low capacity to produce antibody, when 
examined by a modified haemolytic plaque assay. They also reported an 
adjuvant effect to sheep red blood cell (SRBC) antigen in young and 
ageing mice (Johnson et al., 1987). Scbneerson et al., ( 199 1 ) also 
reported that both the primary and secondary serum antibody responses 
to the capsular polysaccharides (CP) antigens in mice were stimulated 
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